Transfers from home to facility-based dialysis: comparisons of HHD, assisted PD and autonomous PD.

home dialysis home hemodialysis nurse assistance peritoneal dialysis technique survival

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 12 10 2023
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 26 7 2024
Statut: epublish

Résumé

Home dialysis therapies such as peritoneal dialysis (PD) and home hemodialysis (HHD) are beneficial for quality of life and patient empowerment. The short technique survival time partly explains their low prevalence. We aimed to assess the risk of transfer to facility-based hemodialysis in patients treated with autonomous PD, assisted PD and HHD. This was a retrospective study using data from the REIN registry of patients starting home dialysis in France from 2002 to 2019. The risks of transfer to facility-based hemodialysis (HD) were compared between three modalities of home dialysis (HHD, nurse-assisted PD, autonomous PD) using survival models with a propensity score (PS)-matched and unmatched cohort of patients. The study included 17 909 patients: 628 in the HHD group, 10 214 in the autonomous PD group, and 7067 in the assisted PD group. During the follow-up period, there were 5347 transfers to facility-based HD. The observed number of transfers was 2458 (13.7%) at 1 year and 5069 (28.3) at 5 years after the start of home dialysis, including 3272 (32%) on autonomous PD, 1648 (23.3%) on assisted PD, and 149 (23.7) on HHD. Owing to clinical characteristics differences, only 38% of HHD patients could be matched to patients from the others group. In the PS-matched cohort, the adjusted Cox model showed no difference in the risk of transfer for assisted PD (cs-HR 1.04, 95% CI 0.75-1.44) or HHD (cs-HR 1.07, 95% CI 0.77-1.48) compared with autonomous PD. Unlike results from other countries, where nurse assistance is not fully available for PD-associated care, there was no difference in technique survival between autonomous PD, nurse-assisted PD, and HHD in France. This discrepancy may be attributed to our inclusion of a broader spectrum of patients who derive significant benefits from assisted PD.

Sections du résumé

Background UNASSIGNED
Home dialysis therapies such as peritoneal dialysis (PD) and home hemodialysis (HHD) are beneficial for quality of life and patient empowerment. The short technique survival time partly explains their low prevalence. We aimed to assess the risk of transfer to facility-based hemodialysis in patients treated with autonomous PD, assisted PD and HHD.
Methods UNASSIGNED
This was a retrospective study using data from the REIN registry of patients starting home dialysis in France from 2002 to 2019. The risks of transfer to facility-based hemodialysis (HD) were compared between three modalities of home dialysis (HHD, nurse-assisted PD, autonomous PD) using survival models with a propensity score (PS)-matched and unmatched cohort of patients.
Results UNASSIGNED
The study included 17 909 patients: 628 in the HHD group, 10 214 in the autonomous PD group, and 7067 in the assisted PD group. During the follow-up period, there were 5347 transfers to facility-based HD. The observed number of transfers was 2458 (13.7%) at 1 year and 5069 (28.3) at 5 years after the start of home dialysis, including 3272 (32%) on autonomous PD, 1648 (23.3%) on assisted PD, and 149 (23.7) on HHD. Owing to clinical characteristics differences, only 38% of HHD patients could be matched to patients from the others group. In the PS-matched cohort, the adjusted Cox model showed no difference in the risk of transfer for assisted PD (cs-HR 1.04, 95% CI 0.75-1.44) or HHD (cs-HR 1.07, 95% CI 0.77-1.48) compared with autonomous PD.
Conclusions UNASSIGNED
Unlike results from other countries, where nurse assistance is not fully available for PD-associated care, there was no difference in technique survival between autonomous PD, nurse-assisted PD, and HHD in France. This discrepancy may be attributed to our inclusion of a broader spectrum of patients who derive significant benefits from assisted PD.

Identifiants

pubmed: 39056065
doi: 10.1093/ckj/sfae094
pii: sfae094
pmc: PMC11270015
doi:

Types de publication

Journal Article

Langues

eng

Pagination

sfae094

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

Déclaration de conflit d'intérêts

The authors have no conflicts of interest to declare.

Auteurs

Antoine Lanot (A)

Normandie Univ, UNICAEN, CHU de Caen Normandie, Néphrologie, Caen, France.
School of medicine, Normandie université, Unicaen, UFR de médecine, Caen, France.
ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.

Clémence Bechade (C)

Normandie Univ, UNICAEN, CHU de Caen Normandie, Néphrologie, Caen, France.
School of medicine, Normandie université, Unicaen, UFR de médecine, Caen, France.
ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.

Cécile Couchoud (C)

REIN Registry, Agence de la Biomédecine, Saint-Denis La Plaine, France.

Mathilde Lassalle (M)

REIN Registry, Agence de la Biomédecine, Saint-Denis La Plaine, France.

François Chantrel (F)

Service de Néphrologie, Groupe Hospitalier de Mulhouse, GHRmsa, Mulhouse, France.

Ayman Sarraj (A)

Centre de Néphrologie le Néphron, Polyclinique St Côme, Compiègne, France.

Maxence Ficheux (M)

Normandie Univ, UNICAEN, CHU de Caen Normandie, Néphrologie, Caen, France.

Annabel Boyer (A)

Normandie Univ, UNICAEN, CHU de Caen Normandie, Néphrologie, Caen, France.
School of medicine, Normandie université, Unicaen, UFR de médecine, Caen, France.
ANTICIPE" U1086 INSERM-UCN, Centre François Baclesse, Caen, France.

Thierry Lobbedez (T)

Normandie Univ, UNICAEN, CHU de Caen Normandie, Néphrologie, Caen, France.
School of medicine, Normandie université, Unicaen, UFR de médecine, Caen, France.

Classifications MeSH